Skip to content
Biotechnology

With an Eye on the Future, Biolog Launches Odin

Biolog, Inc. 2 mins read

HAYWARD, CA / ACCESSWIRE / June 15, 2023 / Biolog, Inc., a leading provider of microbial polyphasic analysis, today announced the launch of the Odin™ system, an all-in-one cellular phenotyping and microbial identification platform. Odin is compatible with all Biolog assays and is available now.

Until today, Biolog's OmniLog® platform was the gold standard for researchers who want actionable insights on microbial metabolic phenotypes. Odin now builds on that foundation while maintaining the core capabilities to incubate, analyze, and compare thousands of microbial and mammalian growth conditions in a single experiment, and to identify aerobic bacteria by its metabolic fingerprint.

Odin changes up the detection method and uses Optical Density (OD), which enables a critical additional modality to measure cell growth. Now on a single platform, researchers can distinguish the effect of a substrate on growth (by OD) and by respiration using our proprietary dye, now an absorbance-based measurement. With the additional Odin capabilities, researchers can now decouple a microbe's respiration rate from its division rate and more fully understand the metabolic output of a cell. With a fully loaded system, Odin records the OD for all conditions for up to 50 plates at a time, measuring the kinetics of cell growth and respiration for thousands of conditions in parallel.

Odin also has broader identification capabilities, including anaerobes, yeast, and filamentous fungi. All told, Odin can identify thousands of microbes, allowing researchers to classify unknown organisms and phenotype them on the same platform.

"We heard from our customers the need to directly measure growth. In a short time, we brought in additional scientific expertise, and built a product development engine. The customer-focused mindset and our dedicated teams have enabled us to quickly meet the needs of our customers," said Robert Wicke, CEO of Biolog.

"Understanding how microbes respond to their environment and food sources is the major economic driver in sustainable agriculture, bioprocessing and synthetic biology, to name just a few areas. We are enthusiastic about the foundation that Odin creates for Biolog and our customers," said Mr. Wicke.

About Biolog

Biolog has the tools, services, and support to provide the microbial phenotypic characterization and polyphasic identification capabilities required to produce functionally relevant insights. Our products and services enable characterization of microbial and mammalian cells as well as identification of thousands of species of bacteria, yeast, and fungi. Learn more at www.biolog.com.

Contact Information:

John Proctor, Ph.D.
CCO
[email protected]
(408)306-0414

SOURCE: Biolog Inc.

.


View source version on accesswire.com:
https://www.accesswire.com/761372/With-an-Eye-on-the-Future-Biolog-Launches-Odin

More from this category

  • Biotechnology, Business Company News
  • 19/02/2026
  • 22:53
Ecopha Group Inc

Ecopha Group Inc. Recognised as One of the Most Innovative Companies to Watch in 2026 by The CEO Vision.

Key Facts: • Recognised by CEO Vision as one of the Most Innovative Companies to Watch in 2026• Incorporated in Delaware, USA in 2024…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 19/02/2026
  • 12:50
Q-Sera

Improving laboratory management and patient outcomes – Q-Sera announces first product launch of its RAPClot(TM) rapid serum blood collection tube technology in Japan

Melbourne, Australia – February 19, 2026 – Q-Sera Pty Ltd, an Australian venture-backed company, today announced that leading Japanese medical device company, Terumo Corporation has launched VenoJect II RAPClotTM evacuated blood collection tubes in the Japanese market. These next-generation tubes incorporate Q-Sera’s patent protected technology and will improve laboratory management and patient outcomes. Even in anticoagulated blood, RAPClot™ rapid serum tubes rapidly produce high quality serum in five minutes. In the case of the VenoJect II RAPClot tubes, formulated to clot up to 6U/ml heparin. This is the first real innovation in the Japanese blood collection tube market in decades,…

  • Biotechnology, Business Company News
  • 12/02/2026
  • 12:22
Jane Morgan Management

BlinkLab Limited (ASX:BB1) Expands Pivotal FDA Trial Network to Nine Elite U.S. Sites Ahead of Imminent Study Commencement

12February 2026 – Sydney, Australia | BlinkLab Limited (ASX:BB1), a leader in AI-powered digital diagnostics, has expanded its U.S. clinical footprint with the onboarding…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.